Gee‐Chen Chang

9.1k total citations · 1 hit paper
55 papers, 3.3k citations indexed

About

Gee‐Chen Chang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Gee‐Chen Chang has authored 55 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pulmonary and Respiratory Medicine, 30 papers in Oncology and 21 papers in Molecular Biology. Recurrent topics in Gee‐Chen Chang's work include Lung Cancer Treatments and Mutations (30 papers), Lung Cancer Diagnosis and Treatment (13 papers) and Lung Cancer Research Studies (10 papers). Gee‐Chen Chang is often cited by papers focused on Lung Cancer Treatments and Mutations (30 papers), Lung Cancer Diagnosis and Treatment (13 papers) and Lung Cancer Research Studies (10 papers). Gee‐Chen Chang collaborates with scholars based in Taiwan, United States and China. Gee‐Chen Chang's co-authors include Pan‐Chyr Yang, Chih‐Yi Chen, Sung‐Liang Yu, Jeremy J.W. Chen, Hsuan‐Yu Chen, James Chih‐Hsin Yang, Chiou-Ling Cheng, Wing‐Kai Chan, Wei J. Chen and Ang Yuan and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Gee‐Chen Chang

54 papers receiving 3.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Five-Gene Signature and Clinical Outcome in Non–Small-Cell Lung Cancer

2007 693 citations Hsuan‐Yu Chen, Sung‐Liang Yu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gee‐Chen Chang Taiwan	31	1.6k	1.6k	1.4k	784	198	55	3.3k
Dean A. Fennell United Kingdom	32	1.5k 0.9×	2.4k 1.5×	1.6k 1.2×	562 0.7×	227 1.1×	114	4.5k
Michelle Casey United States	21	1.6k 1.0×	937 0.6×	2.2k 1.6×	690 0.9×	516 2.6×	58	3.5k
Laura P. Stabile United States	34	1.4k 0.9×	1.3k 0.9×	1.8k 1.3×	504 0.6×	68 0.3×	88	3.4k
Chang‐Qi Zhu Canada	32	2.4k 1.5×	2.9k 1.8×	2.6k 1.9×	1.4k 1.8×	305 1.5×	58	5.3k
Qinghua Zhou China	29	1.2k 0.8×	1.7k 1.1×	1.5k 1.1×	926 1.2×	277 1.4×	215	3.8k
Noriko Yanagitani Japan	37	1.9k 1.2×	2.0k 1.3×	1.9k 1.4×	833 1.1×	357 1.8×	171	4.3k
Michael Bergqvist Sweden	27	1.1k 0.7×	686 0.4×	873 0.6×	579 0.7×	206 1.0×	112	2.5k
Pierre Tennstedt Germany	34	929 0.6×	2.0k 1.3×	787 0.6×	600 0.8×	220 1.1×	134	3.5k
Anne Hansen Ree Norway	30	1.2k 0.7×	506 0.3×	1.3k 1.0×	661 0.8×	476 2.4×	139	3.2k
Marcus V. Cronauer Germany	32	1.7k 1.1×	2.3k 1.5×	698 0.5×	779 1.0×	330 1.7×	73	3.8k

Countries citing papers authored by Gee‐Chen Chang

Since Specialization

Citations

This map shows the geographic impact of Gee‐Chen Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gee‐Chen Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gee‐Chen Chang more than expected).

Fields of papers citing papers by Gee‐Chen Chang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gee‐Chen Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gee‐Chen Chang. The network helps show where Gee‐Chen Chang may publish in the future.

Co-authorship network of co-authors of Gee‐Chen Chang

This figure shows the co-authorship network connecting the top 25 collaborators of Gee‐Chen Chang. A scholar is included among the top collaborators of Gee‐Chen Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gee‐Chen Chang. Gee‐Chen Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hsiao, Yi‐Jing, Min-Shu Hsieh, Gee‐Chen Chang, et al.. (2025). Tp53 determines the spatial dynamics of M1/M2 tumor-associated macrophages and M1-driven tumoricidal effects. Cell Death and Disease. 16(1). 38–38. 4 indexed citations

Wu, Chih‐Ying, et al.. (2025). E3 ligase TRIM8 suppresses lung cancer metastasis by targeting MYOF degradation through K48-linked polyubiquitination. Cell Death and Disease. 16(1). 88–88. 1 indexed citations

Hsu, Kuo-Hsuan, et al.. (2024). Osimertinib as Second- and ≥Third-Line Treatment in Advanced and Recurrence EGFR-Mutant NSCLC Patients Harboring Acquired T790M Mutation. Cancers. 16(24). 4174–4174. 1 indexed citations

Hsu, Kuo-Hsuan, Jing-Wen Huang, Jeng‐Sen Tseng, et al.. (2021). Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients. OncoTargets and Therapy. Volume 14. 2139–2148. 11 indexed citations

Chen, Tzu‐Yu, Huiling Chen, Chin‐Hao Chang, et al.. (2020). Impact of cooking oil fume exposure and fume extractor use on lung cancer risk in non-smoking Han Chinese women. Scientific Reports. 10(1). 6774–6774. 58 indexed citations

Yang, James Chih‐Hsin, Frances A. Shepherd, Dong‐Wan Kim, et al.. (2019). Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report. Journal of Thoracic Oncology. 14(5). 933–939. 164 indexed citations

Scagliotti, Giorgio V., Denis Moro‐Sibilot, Jens Kollmeier, et al.. (2019). A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients. Journal of Thoracic Oncology. 15(1). 80–90. 60 indexed citations

Tseng, Chien‐Hua, Ben‐Jei Tsuang, Chun‐Ju Chiang, et al.. (2019). The Relationship Between Air Pollution and Lung Cancer in Nonsmokers in Taiwan. Journal of Thoracic Oncology. 14(5). 784–792. 139 indexed citations

Chang, Gee‐Chen, Yi‐Ju Chen, Yi‐Chiung Hsu, et al.. (2017). FAM198B Is Associated with Prolonged Survival and Inhibits Metastasis in Lung Adenocarcinoma via Blockage of ERK-Mediated MMP-1 Expression. Clinical Cancer Research. 24(4). 916–926. 26 indexed citations

10.

Mok, Tony, Sarayut Lucien Geater, Wu‐Chou Su, et al.. (2016). A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma. Journal of Thoracic Oncology. 11(10). 1736–1744. 41 indexed citations

11.

Wang, Chi-Chung, Kang‐Yi Su, Hsuan‐Yu Chen, et al.. (2015). HOXA5 Inhibits Metastasis via Regulating Cytoskeletal Remodelling and Associates with Prolonged Survival in Non-Small-Cell Lung Carcinoma. PLoS ONE. 10(4). e0124191–e0124191. 40 indexed citations

12.

Chen, Chun-Chieh, Hsuan‐Yu Chen, Kang‐Yi Su, et al.. (2014). Shisa3 is Associated with Prolonged Survival Through Promoting β-Catenin Degradation in Lung Cancer. American Journal of Respiratory and Critical Care Medicine. 190(4). 433–444. 33 indexed citations

13.

Hung, Pei-Fang, Tse‐Ming Hong, Yi‐Chiung Hsu, et al.. (2013). The Motor Protein KIF14 Inhibits Tumor Growth and Cancer Metastasis in Lung Adenocarcinoma. PLoS ONE. 8(4). e61664–e61664. 38 indexed citations

14.

Lo, Yen-Li, Chin‐Fu Hsiao, Gee‐Chen Chang, et al.. (2012). Risk factors for primary lung cancer among never smokers by gender in a matched case–control study. Cancer Causes & Control. 24(3). 567–576. 44 indexed citations

15.

Yang, Shi‐Yi, Tsung‐Ying Yang, Kun‐Chieh Chen, et al.. (2011). EGFR L858R Mutation and Polymorphisms of Genes Related to Estrogen Biosynthesis and Metabolism in Never-Smoking Female Lung Adenocarcinoma Patients. Clinical Cancer Research. 17(8). 2149–2158. 26 indexed citations

16.

Salto‐Tellez, Manuel, Ming‐Sound Tsao, Jin‐Yuan Shih, et al.. (2011). Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer: A Combined Clinical-Molecular Pathological Approach. Journal of Thoracic Oncology. 6(10). 1663–1669. 33 indexed citations

17.

Hsu, Yi‐Chiung, Shinsheng Yuan, Hsuan‐Yu Chen, et al.. (2009). A Four-Gene Signature from NCI-60 Cell Line for Survival Prediction in Non–Small Cell Lung Cancer. Clinical Cancer Research. 15(23). 7309–7315. 42 indexed citations

18.

Pan, Szu‐Hua, Shuenn-Chen Yang, Sung‐Liang Yu, et al.. (2008). Claudin-1 Is a Metastasis Suppressor and Correlates with Clinical Outcome in Lung Adenocarcinoma. American Journal of Respiratory and Critical Care Medicine. 179(2). 123–133. 146 indexed citations

19.

Chang, Gee‐Chen, Ko‐Jiunn Liu, Chia‐Ling Hsieh, et al.. (2006). Identification of α-Enolase as an Autoantigen in Lung Cancer: Its Overexpression Is Associated with Clinical Outcomes. Clinical Cancer Research. 12(19). 5746–5754. 128 indexed citations

20.

Perng, Reury-Perng, Chih‐Yi Chen, Gee‐Chen Chang, et al.. (2006). Revisit of 1997 TNM Staging System—Survival Analysis of 1112 Lung Cancer Patients in Taiwan. Japanese Journal of Clinical Oncology. 37(1). 9–15. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact